Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
January 26 2009 - 4:30PM
PR Newswire (US)
Mihalik Brings Track Record for Generating Sales and Profits in the
Diabetes Arena SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) announced today that Vincent P.
Mihalik has been appointed Senior Vice President, Sales and
Marketing and Chief Commercial Officer. Mr. Mihalik brings more
than 30 years of experience across multiple commercial roles,
including global product development, sales and sales management,
product launches and brand management. His career has focused on
diabetes, with numerous leadership roles at leading pharmaceutical
companies. Before joining Amylin, Mr. Mihalik was Vice President of
Global Brand Development Diabetes and Endocrine Platform Team
Leader at Eli Lilly and Company, where he managed the second
largest therapeutic area for the company and was responsible for
product development beyond Phase 2b to launch for lifecycle
planning and commercialization. Previously, Mr. Mihalik was
Business Unit Head of Diabetes Care for Lilly U.S., where he was
responsible for the launch, sales and marketing for Actos(R)
(pioglitazone), insulin injection pens (Humulin(R), Humalog(R)) and
the preparation for the launch of Cialis(R) (tadalafil) in the U.S.
Mr. Mihalik has extensive previous experience in diabetes and has a
successful track record in leadership at a number of companies
focused on improving care for patients. These include: Roche
Diagnostics Corporation (Senior Vice President and General Manager
for Lab Systems and Molecular Biochemicals), Boehringer Mannheim
Group (Executive Vice President of Human Resources for BM Global
and President Diabetes Care North America) and Baxter Healthcare
(President Scientific Products Biomedical and General Manager,
Pandex Diagnostic Research and Development Center). "Vince brings
extensive sales and marketing expertise in the area of diabetes,
and has a proven track record for increasing sales and profits. He
is a seasoned professional who has successfully managed multiple
new product launches," said Daniel M. Bradbury, President and Chief
Executive Officer, Amylin Pharmaceuticals. "Vince will add
significant value to Amylin as we look to grow BYETTA and SYMLIN
revenue and finalize our commercial plans for exenatide once
weekly. As an integral part of our executive committee, we look
forward to the strategic contributions Vince will make, as well as
the fresh perspective he will bring during this exciting time." Mr.
Mihalik will oversee marketing and sales for Amylin's two marketed
products, BYETTA(R) (exenatide) injection and SYMLIN(R)
(pramlintide acetate) injection, as well as the launch and
commercialization of exenatide once weekly, Amylin's lead
development compound. He will become a member of Amylin's executive
committee. About Amylin Pharmaceuticals Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two first-
in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research
and development activities leverage the Company's expertise in
metabolism to develop potential therapies to treat diabetes and
obesity. Amylin is headquartered in San Diego, California. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. This press release contains forward-looking
statements about Amylin. The Company's actual results could differ
materially from those discussed in this press release due to a
number of risks and uncertainties, including risks that BYETTA and
SYMLIN, and the revenues we generate from these products, may be
affected by competition, unexpected new data, technical issues, or
manufacturing and supply issues; and risks that our NDAs for
product candidates, such as exenatide once weekly, may not be
submitted timely or receive FDA approval. These and other risks are
more fully described in the Company's recently filed Form 10-Q.
Amylin disclaims any obligation to update these forward-looking
statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT:
Media, Anne Erickson of Amylin Pharmaceuticals, Inc.,
+1-858-754-4443, or Cell, +1-858-349-3195, Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024